Organ Recovery Biotech Angion Biomedica Corp. Files For A $35 Million IPO

Angion Biomedica, which develops a therapy for injured organs that triggers the body's natural regenerative process, filed on Monday with the SEC to raise up to $35 million in an initial public offering. Its lead candidate is designed to speed the recovery time for patients after a kidney transplant, but Angion believes it can be used to prevent and repair damage to other organs as well.

Help employers find you! Check out all the jobs and post your resume.